Drugs / RUZOTOLIMOD
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03530917 | May 2018 → May 2019 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02956850 | Dec 2016 → Jun 2021 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04225715 | Jul 2020 → Jul 2024 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RUZOTOLIMOD | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095082 ↗ |
| Known as | RG7854 | “We aimed to assess the safety and tolerability of RO7020531 (also called RG7854), a prodrug of the TLR7 agonist RO7011785” PMID 36509100 ↗ Dec 2022 |
| Known as | RO7020531 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04225715 ↗ |
| Modality | Small molecule | — CHEMBL5095082 ↗ |
| Route | Oral | “Study medication was administered orally to participants after they had fasted.” PMID 36509100 ↗ Dec 2022 |
| Target | TLR7 | “RO7020531 (also called RG7854), a prodrug of the TLR7 agonist RO7011785” PMID 36509100 ↗ Dec 2022 |